Interleukin 2 and interferon alpha-2a do not improve anti-tumour activity of 5-fluorouracil in advanced colorectal cancer.

about

Potential of interferon-alpha in solid tumours: part 2.

P2860

Q34984858-A17CBC6B-88FD-43C3-91F1-70D233C42BBE

P2860

Interleukin 2 and interferon alpha-2a do not improve anti-tumour activity of 5-fluorouracil in advanced colorectal cancer.

Item

http://www.wikidata.org/entity/Q36136350

description

1996 nî lūn-bûn

@nan

1996年の論文

@ja

1996年論文

@yue

1996年論文

@zh-hant

1996年論文

@zh-hk

1996年論文

@zh-mo

1996年論文

@zh-tw

1996年论文

@wuu

1996年论文

@zh

1996年论文

@zh-cn

name

Interleukin 2 and interferon a ...... in advanced colorectal cancer.

@ast

Interleukin 2 and interferon a ...... in advanced colorectal cancer.

@en

type

Item

label

Interleukin 2 and interferon a ...... in advanced colorectal cancer.

@ast

Interleukin 2 and interferon a ...... in advanced colorectal cancer.

@en

prefLabel

Interleukin 2 and interferon a ...... in advanced colorectal cancer.

@ast

Interleukin 2 and interferon a ...... in advanced colorectal cancer.

@en

P1476

Interleukin 2 and interferon a ...... in advanced colorectal cancer.

@en

P2093

Goey SH

http://www.w3.org/2001/XMLSchema#string

Gratama JW

http://www.w3.org/2001/XMLSchema#string

Mertelsmann RH

http://www.w3.org/2001/XMLSchema#string

Osterwalder B

http://www.w3.org/2001/XMLSchema#string

Primrose JN

http://www.w3.org/2001/XMLSchema#string

Stoter G

http://www.w3.org/2001/XMLSchema#string

Verweij J

http://www.w3.org/2001/XMLSchema#string

Ward U

http://www.w3.org/2001/XMLSchema#string

P2860

Fluorinated pyrimidines, a new class of tumour-inhibitory compounds

Treatment of metastatic colorectal cancer patients with 5-fluorouracil in combination with recombinant subcutaneous human interleukin-2 and alpha-interferon.

Paradoxical effects of 5-FU/folinic acid on lymphokine-activated killer (LAK) cell induction in patients with colorectal cancer.

Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.

Modulation of immune parameters in patients with metastatic renal-cell cancer receiving combination immunotherapy (IL-2, IFN alpha and autologous IL-2-activated lymphocytes).

MHC class I genes controlling the metastatic phenotype of tumor cells.

Antitumor effects of interferon.

A phase II study of advanced colorectal cancer patients treated with combination 5-fluorouracil plus leucovorin and subcutaneous interleukin-2 plus alpha interferon.

Interactive effects of alpha-interferon A/D and interleukin 2 on murine lymphokine-activated killer activity: analysis at the effector and precursor level.

Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer.

P2888

bjc.1996.670

P304

2018-2023

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.1996.670

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

1996-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

14228394

http://www.w3.org/2001/XMLSchema#string

P698

8980407

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

2074801

http://www.w3.org/2001/XMLSchema#string

Interleukin 2 and interferon alpha-2a do not improve anti-tumour activity of 5-fluorouracil in advanced colorectal cancer.

about

P2860

P2860

Interleukin 2 and interferon alpha-2a do not improve anti-tumour activity of 5-fluorouracil in advanced colorectal cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P921

P932